drugset
drugset / Trial / NCT03184935

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

NCT03184935 ↗

Phase 1/2 Suspended 40 enrolled Sclnow Biotechnology Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.

Timeline

Start
2026-12-31
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic umbilical cord mesenchymal stem cells Cell therapy — Intravenous
Background Decitabine Small molecule 20 mg/m2 —

Indications

myelodysplastic syndrome